Sliwa et al. JACC 2004;44:
|
|
- Roxanne Paul
- 6 years ago
- Views:
Transcription
1 TREATMENT OF ADVANCED HEART FAILURE HEART DISEASE IN KENTUCKY Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation November 1, 2009 TOPICS FOR DISCUSSION ACE inhibitors & Beta-blockers Diuretics Cardiac resynchronization Cardiac transplantation ACE INHIBITORS Standard therapy for heart failure Best randomized trial data for captopril, lisinopril, and enalapril All are now generic and cheap! Start low dose and titrate upwards to goal Enalapril: 2.5 mg qd-bid to mg bid Lisinopril: 2.5 mg qd to mg qd ARB can be used if ACEi intolerant BETA BLOCKERS Standard therapy for heart failure Best randomized trial data for metoprolol succinate (Toprol XL) and carvedilol (Coreg) Both are now generic Start low dose and titrate upwards to goal Toprol XL: 25 mg qd to 200 mg qd carvedilol: mg bid to 25 mg bid COMET trial suggested better outcomes with carvedilol than with metoprolol (although metoprolol tartrate was used) ACE inhibitors are commonly instituted first Beneficial effects of BB were found after use of ACE inhibitors was standard-care BB contraindicated if patients are significantly volume overloaded Is this titration scheme necessary? 1
2 Sliwa et al. (2004) evaluated initiation of therapy with carvedilol either before (n=38) or after (n=40) perindopril therapy in newly diagnosed NYHA II-III III HF patients Alternative agent was added at 6 months (target doses: carvedilol 25 mg bid, perindopril 8 mg qd) Endpoint: LVEF and functional class at 1 year Carvedilol first 12 mo: Better improvement in NYHA class Better improvement in LVEF Lower dose of furosemide Higher dose of carvedilol (43 17 mg vs mg) Sliwa et al. JACC 2004;44: CIBIS III study randomized 1010 patients with class II-III III systolic HF to monotherapy with bisoprolol (target dose 10 mg qd) or enalapril (target dose 10 mg bid) for 6 months, followed by their combination for 6-24 months Primary end-point: mortality or hospitalization Trend towards better survival in bisoprolol first group Trend towards more HF hospitalization in bisoprolol first group Safe and efficacious to initiate CHF treatment with beta- blockers Not necessary that ACE inhibitors be used before beta-blockers blockers Titration of both drugs can be accomplished at the same time Volume status needs to be managed before beta-blockers blockers are aggressively titrated ACE INHIBITORS ATLAS study randomized 3164 NYHA II- IV systolic HF patients to low dose lisinopril (2.5 to 5.0 mg qd) or high dose (32.5 to 35 mg qd) LVEF < 30% No BB use (trial published in 1999) 2
3 ACE INHIBITORS High-dose group had a nonsignificant 8% lower risk of death (p = 0.13) Significant 12% lower risk of death or hospitalization for any reason and 24% fewer hospitalizations for HF in high dose group ACE INHIBITORS Using dose that is similar to that used in clinical trials has meaningful benefit over low dose The differences between intermediate-dose dose and high-dose lisinopril is likely to be small, if present at all Is the same thing true of beta-blockers blockers in heart failure? Packer et al. Circ 1999;100: BETA-BLOCKERSBLOCKERS McAlister et al. (2009) performed a meta-analysis analysis on 23 BB trials in systolic HF to determine if the survival benefits were associated with BB dose or the magnitude of heart rate reduction Medications: metoprolol (5), carvedilol (9), bisoprolol (3), bucindolol (3), atenolol (1), and nebivolol (2) BETA-BLOCKERSBLOCKERS For every HR reduction of 5 beats/min, a significant 18% reduction in the risk of death occurred No significant relationship between all-cause mortality and BB dosing was observed McAlister et al. Ann Intern Med 2009;150: McAlister et al. Ann Intern Med 2009;150: BETA BLOCKERS Other investigators have observed that HF patients with higher baseline HR exhibit the greatest improvements in LVEF with BB therapy and that greater reductions in HR are associated with greater improvements in LVEF Optimal HR is unknown If substantial HR reduction is achieved with low-dose BB, should you keep titrating? Is there any benefit to using dosing higher than trial doses if HR reduction is suboptimal? MY OPINION If limited by BP, it is better to get a patient on small doses of both classes of medications, as opposed to a moderate dose of one Achieving i maximal dose of BB is likely l more important than achieving maximal dose of ACE inhibitor If tolerated, discharge patients with both medications, even if low dose 3
4 DIURETICS Aldosterone antagonist (spironolactone) Loop diuretics SPIRONOLACTONE RALES randomized 1663 systolic heart failure patients (LVEF < 35%; NYHA class III/IV) to spironolactone or placebo Serum Cr < 2.5, K < 5.0 Initial dose 25 mg qd, increased to 50 mg qd if no benefit, no side effects 94 % on ACEi; 10% on BB SPIRONOLACTONE IN THE REAL WORLD Retrospective studies have identified inappropriate use of spironolactone in patients with renal insufficiency as well as less than ideal follow-up Bozkurt et al. in a retrospective review of 104 pts reported 10% rate of serious hyperkalemia (K+ > 6) LOOP DIURETICS Loop diuretics (IV) are a mainstay of therapy for AHFS 75-80% in ADHERE received IV diuretics Reduce left ventricular filling pressures Reduce central venous pressure 40 mg furosemide = 20 mg torsemide = 1 mg bumetanide Bozkurt et al. JACC 2003; 41: PROBLEMS WITH DIURETICS Adverse neurohormonal activation Increased plasma renin, aldosterone, norepinephrine In SOLVD trial, use of long-term diuretics was associated with a 1.33 fold increase in risk of arrhythmic death after correcting for other mortality risk factors Postdiuretic sodium rebound as a result of poor dietary compliance Given short half-life life of diuretics, there is a significant amount of time where the tubular concentration of the diuretic is subtherapeutic. CARDIO-RENAL RENAL SYNDROME Low cardiac output is not necessary and many patients have preserved LVEF (diastolic HF) and/or elevated BP Registry of 1004 patients admitted with CHF found worsening renal function during hospitalization (Cr rise > 0.3 mg/dl) in 27% which was statistically associated with hospital deaths and LOS > 10 days Gheorghiade et al. JACC 2009; 53:
5 CARDIO-RENAL RENAL SYNDROME CARDIO-RENAL RENAL SYNDROME Animal studies have demonstrated that temporary elevation of CVP can lead to worsened renal function via congestion of the renal veins Mullens et al. (JACC 2009) recently showed in 145 patients with AHFS that patients who developed worsening renal function had greater CVP upon admission as well as greater CVP following medical therapy Renal function did not correlate with other hemodynamic variables Mullens et al. JACC 2009;53: COMBATING DIURETIC RESISTANCE Addition of thiazide diuretic to a loop diuretic results in greater diuresis i and naturesis than increasing dose of loop diuretic alone COMBATING DIURETIC RESISTANCE Dormans et al. (JACC 1996) randomized 20 CHF patient on high doses of oral lasix (> 250 mg/day) to intravenous bolus therapy versus the same dose given as a continuous infusion for 1 day Urinary volume and urinary excretion of sodium were both significantly greater at 8 hours and 24 hours in the continuous infusion group (mean daily dose of 690 mg) Less peak concentration with continuous infusion may lessen risk of ototoxicity Stewart JH et al. BMJ 1965; 5473: DOES THE CHOICE OF DIURETIC MATTER? Oral torsemide may be better and more reliably absorbed than either furosemide or bumetanide, with more consistent bioavailability Furosemide in particular has variable absorption Response to intravenous doses likely to be similar DIURETICS Use lowest dose possible to achieve effective diuresis Loop + thiazide combination and consideration of continuous infusion are options for those difficult to diurese Worsening renal function is a not a contraindication to diuretic therapy 5
6 CARDIAC RESYNCHRONIZATION THERAPY (CRT) CARDIAC RESYNCHRONIZATION THERAPY (CRT) Biventricular pacemaker / ICD Left ventricular dyssynchrony prevalent in systolic HF Indicated in: Chronic systolic HF on optimal medical Rx NYHA class III/IV QRS duration > 120 seconds Right Atrial Lead Left Ventricular Lead Right Ventricular Lead CRT alone (without ICD) improved survival in chronic class III/IV HF patients t with QRS > 120 ms over OMT Benefit greater in pts with QRS duration > 160 msec Cleland J et al. NEJM 2005; 352: CRT CRT IN NYHA I/II HEART FAILURE Can CRT be utilized in patients with less severe heart failure? Previous studies have suggested that CRT can lead to positive remodeling including improvement in left ventricular end-systolic volumes MADIT-CRT was designed to determine if CRT could improve outcomes in NYHA I-II II HF patients with QRS duration > 130 ms Benefit of CRT driven by significant 41% reduction in HF events over 2.4 years (no difference in mortality) Benefit confined to those with QRS duration > 150 msec Moss AJ et al. NEJM 2009; 361 CRT Future guidelines may incorporate the latest data suggesting benefit of CRT in class I/II HF, particularly those with QRS duration > 150 msec Procedure does have increased risk compared to ICD alone Cost effectiveness? CARDIAC TRANSPLANTATION Treatment option for systolic heart failure refractory to maximal medical therapy Limited it by supply of donor organs heart transplants / year in US Extensive patient evaluation required Medical, psychosocial, insurance, etc. 6
7 TRANSPLANT EVALUATION WHEN TO REFER Symptoms limiting quality of life Recurrent heart failure admissions despite maximal therapy Worsening end-organ function (renal, hepatic) Before they become irreversible Refractory ventricular arrhythmias For younger patients, may be useful to be plugged into the system Mehra MR et al. Listing Criteria for Heart Transplantation. J Heart Lung Transplant 2006;25: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 (Transplants: 1/1982 6/2006) ADULT HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: June 2006) 100 All comparisons significant at p < % Surv vival (%) (N=18,854) 854) (N=35,146) /2006 (N=12,369) 20 HALF-LIFE : 8.8 years; : 10.5 years; /2006: NA Years 80% 60% 40% 20% 0% No Activity Limitations Performs with Some Assistance Requires Total Assistance 1 Year (N = 15,388) 3 Years (N = 13,600) 5 Years (N = 11,698) 7 Years (N = 9,306) ISHLT 2008 J Heart Lung Transplant 2008;27: ISHLT 2008 J Heart Lung Transplant 2008;27: Last updated based on data as of December 2006 CONTRAINDICATIONS Active substance abuse Lack of social support Severe peripheral vascular disease Severe lung disease Active viral hepatitis / HIV Recent malignancy VAD Option for patients with end-stage HF and who are not candidates for transplantation, or who cannot wait for transplant Requires major cardiothoracic surgery with similar contraindications as transplant Devices are getting smaller and safer Rose EA et al. NEJM 2001;345:
8 REMATCH (2001) DESTINATION L-VAD HEARTMATE II Rose EA et al. NEJM 2001;345: patients with end-stage CHF, 80% requiring IV inotropic therapy, randomized to medical therapy versus HeartMate I LVAD (pulsatile device) Patients were not transplant candidates Cause of death in LVAD group was predominantly sepsis, LVAD failure, and CVA Pagani FD et al. JACC 2009;54: Continuous flow rotary pump External drive line still needed Smaller size allows for use in smaller patients, females Recent studies have shown lower adverse events (stroke, bleeding, infection) compared to older, larger devices HEARTMATE II WHAT ABOUT THE COST? HM II device appears to be safe for bridge to transplant and an improvement over older pulsatile devices No randomized study versus transplant Learning curve is present Outcomes not assessed after transplant does VAD prior to transplant constitute a risk factor for poor outcome? Hernandez et al. (JAMA, 2008) examined Medicare data for patients who underwent VAD implant between 2/2000 and 6/2006 Primary device group (n = 1476) Post cardiotomy (n =1467) 1 year survival was 51.6% in the primary device group and 30.8% in post-cardiotomy group Mean 1-year Medicare payments for inpatient care was $ in the primary device group and $ in the post-cardiotomy group CONCLUSION QUESTIONS? Advanced heart failure is a severe, debilitating illness that requires a multidisciplinary approach Evidence based therapy is still underutilized Referral for transplantation should be considered in acceptable candidates Navin Rajagopalan n.rajagopalan@uky.edu Phone: (UK MD) Cell:
9 For each of the following medications used in chronic HF, specify if they improve mortality, worsen mortality, or are neutral A. Enalapril IMPROVE B. Digoxin NEUTRAL C. Amlodipine NEUTRAL D. Dobutamine WORSEN E. Nesiritide???????? Which of the following statements is true about management of chronic HF? A. ACE inhibitors should be started before beta blockers B. Carvedilol is the only FDA approved beta-blocker blocker for heart failure C. ACE inhibitors are contraindicated in HF patients with serum creatinine > 2.0 D. Despite benefits seen with hydralazine / nitrates in African Americans, African Americans with HF should still be started on ACE inhibitors first E. If a HF patient develops cough from ACE inhibitor, it is advisable not to switch to an angiotensin receptor blocker (ARB) given the lack of data using ARBs in heart failure DIURETICS IN HEART FAILURE Which of the following has proven mortality benefit in patients with systolic heart failure? A. Furosemide B. Spironolactone C. Torsemide D. Chlortalidone E. None of the above DEVICE THERAPY 48 year old female presents with progressive SOB following mild viral illness Subsequent echo shows dilated LV (LVEDD 6.8 cm) and EF 20% ECG shows LBBB which is old (patient has known of LBBB since age 25). QRS duration 150 msec LHC showed no CAD Started on carvedilol and lisinopril and medications are titrated upwards Symptoms improve and patient is back to baseline, exercising, in NYHA class I Repeat echo in 3 months shows LVEF 25% DEVICE THERAPY Patient is referred to Electrophysiology. What device is recommended by the current heart failure guidelines? A. No device B. Dual chamber pacemaker C. Biventricular pacemaker / ICD (i.e CRT) D. Dual chamber ICD CARDIAC TRANSPLANTATION All of the following statements are true, except: A. Following cardiac transplantation, 5 year survival is 75% and 10 year survival is 50% B. History of drug abuse including smoking is a contraindication for cardiac transplantation C. For patients who unable to receive a heart transplant in time, left ventricular assist devices (VAD) can be utilized as a bridge to transplantation D. Referral for heart transplantation should be considered if a patient remains significantly limited despite optimal medical therapy 9
Contemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More informationCASE STUDIES IN ADVANCED HEART FAILURE
CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationOutline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationChronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More information3/2/2017. Identifying the Patient for Advanced Therapies. Why is Identifying the Adv HF patient important? CHF Stages and Steps of Treatment
Identifying the Patient for Advanced Therapies Cindy Bither Chief NP- Adv HF Program Medstar Heart and Vascular Institute Stage A High risk with no symptoms Stage B Structural heart disease, no symptoms
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationWHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine
WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF
More informationUpdates in Diagnosis & Management of CHF
Updates in Diagnosis & Management of CHF N. Goldberg, DO April 30, 2011 CHF CHF is reaching an epidemic level in U.S. and continues to worsen over time Reasons are: HTN Dm with sedentary lifestyle and
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHeart Failure Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital
Heart Failure 2012 Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital PRELOAD COWS Reduction in milk production INOTROPY & HEART RATE AFTERLOAD DISTRIBUTION NETWORK THE CLASSIC APPROACH
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationHEART FAILURE KEEPING YOUR PATIENT AT HOME
HEART FAILURE KEEPING YOUR PATIENT AT HOME SUZANNE FRAZIER MS, CRNP, NP-C, CHFN HEART FAILURE DISEASE MANAGEMENT COORDINATOR PENN STATE HERSHEY HEART & VASCULAR INSTITUTE IMPACT OF HEART FAILURE In 2010,
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationEpidemiology of Symptomatic Heart Failure in the U.S.
William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology Director, Division of Cardiovascular Medicine Deputy Director Davis Heart and Lung Research Institute
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationNew Strategies For Treating Patients With Chronic Heart Failure
New Strategies For Treating Patients With Chronic Heart Failure Barry Greenberg MD Professor of Medicine Director, Advanced Heart Failure Treatment Program University of California, San Diego Disclosures
More informationSara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012
Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012 Disclosure: Dr. Weiss has no significant financial interest in any of the products or manufacturers mentioned.
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationTarget dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic
Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic June Chen 1, Charlotte Galenza 1, Justin Ezekowitz 2,3,
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationCHF ICU to community. Disclosure slide CHF. Diagnosis. Diagnosis. Diagnostic modalties Therapeutic modalities. Talks. Advisory boards.
CHF ICU to community CHF Diagnostic modalties Therapeutic modalities ICU Pacer/ ICD Medication CHF clinic ASV - Nejm. Sept. 17,2015. Advanced care directives Disclosure slide Talks most companies Advisory
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More information5 Important Things to Know About Heart Failure. Kia Afshar, MD
5 Important Things to Know About Heart Failure Kia Afshar, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1) Understand
More informationTri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM
Tri-City Cardiology Consultants FIFTH ANNUAL SYMPOSIUM Faculty Disclosure Banner Baywood Medical Center -Chief of Staff FIFTH ANNUAL SYMPOSIUM NYHA class III-IV symptoms Clinical signs of fluid retention
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More informationReview Article. Pharmacotherapy of Heart Failure with Reduced LVEF. Sachin Mukhedkar, Ajit Bhagwat
Review Article Vidarbha Journal of Internal Medicine Volume 22 January 2017 Pharmacotherapy of Heart Failure with Reduced LVEF 1 2 Sachin Mukhedkar, Ajit Bhagwat ABSTRACT Heart failure with reduced ejection
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationDisclosures. Preventing Heart Failure Re-admissions in Deaths Due to Cardiovascular Disease (United States: ) Heart Failure
29 th Annual Cardiology for Clinicians Spring Symposium Workshop #3 Alumni Hallway, Northeastern Conference Room, 1-9525 Thursday, May 5, 2016 Preventing Heart Failure Re-admissions in 2016 Leway Chen,
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationHeart Failure CTSHP Fall Seminar
Heart Failure CTSHP Fall Seminar Laurajo Ryan, PharmD, MSc, BCPS, CDE Pharmacist Learning Objectives Outline the pathophysiology of heart failure List triggers for decompensated heart failure Describe
More informationHeart Failure in 2012 with reference to NICE Guidance Dr Maurice Pye Consultant Cardiologist York District Hospital
Heart Failure in 2012 with reference to NICE Guidance 2010 Dr Maurice Pye Consultant Cardiologist York District Hospital A little over elaborate,do not include ECG or CXR If clinical suspicion is high
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationImplantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred
Implantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred Professor John GF Cleland University of Hull Kingston-upon-Hull United Kingdom Conflict of Interest: Funding or Speakers
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost
More information